367 related articles for article (PubMed ID: 10960479)
21. CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2.
Sasaki A; Yasukawa H; Shouda T; Kitamura T; Dikic I; Yoshimura A
J Biol Chem; 2000 Sep; 275(38):29338-47. PubMed ID: 10882725
[TBL] [Abstract][Full Text] [Related]
22. Genetic evidence for an additional factor required for erythropoietin-induced signal transduction.
Gaffen SL; Lai SY; Longmore GD; Liu KD; Goldsmith MA
Blood; 1999 Jul; 94(1):74-86. PubMed ID: 10381500
[TBL] [Abstract][Full Text] [Related]
23. A constitutively activated chimeric cytokine receptor confers factor-independent growth in hematopoietic cell lines.
Shikama Y; Barber DL; D'Andrea AD; Sieff CA
Blood; 1996 Jul; 88(2):455-64. PubMed ID: 8695792
[TBL] [Abstract][Full Text] [Related]
24. Erythropoietin induces association of the JAK2 protein tyrosine kinase with the erythropoietin receptor in vivo.
Miura O; Nakamura N; Quelle FW; Witthuhn BA; Ihle JN; Aoki N
Blood; 1994 Sep; 84(5):1501-7. PubMed ID: 8068943
[TBL] [Abstract][Full Text] [Related]
25. Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway.
Okutani Y; Kitanaka A; Tanaka T; Kamano H; Ohnishi H; Kubota Y; Ishida T; Takahara J
Oncogene; 2001 Oct; 20(45):6643-50. PubMed ID: 11641791
[TBL] [Abstract][Full Text] [Related]
26. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma.
Lai SY; Childs EE; Xi S; Coppelli FM; Gooding WE; Wells A; Ferris RL; Grandis JR
Oncogene; 2005 Jun; 24(27):4442-9. PubMed ID: 15856028
[TBL] [Abstract][Full Text] [Related]
27. Erythropoietin activates Raf1 by an Shc-independent pathway in CTLL-EPO-R cells.
Barber DL; Corless CN; Xia K; Roberts TM; D'Andrea AD
Blood; 1997 Jan; 89(1):55-64. PubMed ID: 8978277
[TBL] [Abstract][Full Text] [Related]
28. Erythropoietin induces activation of Stat5 through association with specific tyrosines on the receptor that are not required for a mitogenic response.
Quelle FW; Wang D; Nosaka T; Thierfelder WE; Stravopodis D; Weinstein Y; Ihle JN
Mol Cell Biol; 1996 Apr; 16(4):1622-31. PubMed ID: 8657137
[TBL] [Abstract][Full Text] [Related]
29. Erythropoietin and interleukin-2 activate distinct JAK kinase family members.
Barber DL; D'Andrea AD
Mol Cell Biol; 1994 Oct; 14(10):6506-14. PubMed ID: 7935373
[TBL] [Abstract][Full Text] [Related]
30. Activation of the JAK1-STAT5 pathway by binding of the Friend virus gp55 glycoprotein to the erythropoietin receptor.
Yamamura Y; Senda H; Noda M; Ikawa Y
Leukemia; 1997 Apr; 11 Suppl 3():432-4. PubMed ID: 9209415
[TBL] [Abstract][Full Text] [Related]
31. Enhancement of erythropoietin-stimulated cell proliferation by Anandamide correlates with increased activation of the mitogen-activated protein kinases ERK1 and ERK2.
Valk P; Verbakel S; von Lindern M; Löwenberg B; Delwel R
Hematol J; 2000; 1(4):254-63. PubMed ID: 11920199
[TBL] [Abstract][Full Text] [Related]
32. Protein kinase B (c-Akt), phosphatidylinositol 3-kinase, and STAT5 are activated by erythropoietin (EPO) in HCD57 erythroid cells but are constitutively active in an EPO-independent, apoptosis-resistant subclone (HCD57-SREI cells).
Bao H; Jacobs-Helber SM; Lawson AE; Penta K; Wickrema A; Sawyer ST
Blood; 1999 Jun; 93(11):3757-73. PubMed ID: 10339482
[TBL] [Abstract][Full Text] [Related]
33. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
Ueda F; Tago K; Tamura H; Funakoshi-Tago M
J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
[TBL] [Abstract][Full Text] [Related]
34. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin.
Witthuhn BA; Quelle FW; Silvennoinen O; Yi T; Tang B; Miura O; Ihle JN
Cell; 1993 Jul; 74(2):227-36. PubMed ID: 8343951
[TBL] [Abstract][Full Text] [Related]
35. Requirement for JAK2 in erythropoietin-induced signalling pathways.
Bittorf T; Jaster R; Lüdtke B; Kamper B; Brock J
Cell Signal; 1997 Jan; 9(1):85-9. PubMed ID: 9067635
[TBL] [Abstract][Full Text] [Related]
36. The extended box 2 subdomain of erythropoietin receptor is nonessential for Jak2 activation yet critical for efficient mitogenesis in FDC-ER cells.
He TC; Jiang N; Zhuang H; Quelle DE; Wojchowski DM
J Biol Chem; 1994 Jul; 269(28):18291-4. PubMed ID: 8034573
[TBL] [Abstract][Full Text] [Related]
37. STAT1 is involved in signal transduction in the EPO induced HEL cells.
Chu J; Gui CY; Fan J; Tang XD; Qiao RL
Cell Res; 1998 Jun; 8(2):105-17. PubMed ID: 9669026
[TBL] [Abstract][Full Text] [Related]
38. Activation of 70-kDa S6 kinase, induced by the cytokines interleukin-3 and erythropoietin and inhibited by rapamycin, is not an absolute requirement for cell proliferation.
Calvo V; Wood M; Gjertson C; Vik T; Bierer BE
Eur J Immunol; 1994 Nov; 24(11):2664-71. PubMed ID: 7957559
[TBL] [Abstract][Full Text] [Related]
39. Tyrosine 425 within the activated erythropoietin receptor binds Syp, reduces the erythropoietin required for Syp tyrosine phosphorylation, and promotes mitogenesis.
Tauchi T; Damen JE; Toyama K; Feng GS; Broxmeyer HE; Krystal G
Blood; 1996 Jun; 87(11):4495-501. PubMed ID: 8639815
[TBL] [Abstract][Full Text] [Related]
40. Co-stimulation with stem cell factor and erythropoietin enhances migration of c-Kit expressing cervical cancer cells through the sustained activation of ERK1/2.
Aguilar C; Aguilar C; Lopez-Marure R; Jiménez-Sánchez A; Rocha-Zavaleta L
Mol Med Rep; 2014 May; 9(5):1895-902. PubMed ID: 24626629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
